Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Absorbs 130 Medical Representatives From Merck KGaA

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo announced July 16 that its German subsidiary agreed to take in 130 medical representatives from Merck KGaA. Since Merck KGaA's decision not to continue marketing activities to medical facilities for drugs whose patents have expired, Daiichi Sankyo decided to take half of the medical representatives and merge them into its own sales force. Currently, 70 percent of Daiichi Sankyo's sales come from the Japanese domestic market. The company hopes to reach 70 percent of sales from the overseas market by 2015. The company is rapidly expanding business in Europe, and in Germany, it has acquired bio-pharmaceutical company Morphosys and antibody maker U3 Pharma. (Click here for more - Japanese language) "In Germany Daiichi Sankyo Takes In 130 Medical Representatives From Merck" - NNA News (7/18/08)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel